BladenCL, SalgadoD, MongesS, FoncubertaME, KekouK, KosmaK, DawkinsH, LamontL, RoyAJ, et al. (2015). The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat, 36:395–402.
2.
Aartsma-RusA, FokkemaI, VerschuurenJ, GinjaarI, van DeutekomJ, van OmmenGJ and den DunnenJT. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat, 30:293–299.
3.
Aartsma-RusA and KriegAM. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther, 27:1–3.
4.
CharlestonJS, SchnellFJ, DworzakJ, DonoghueC, LewisS, ChenL, YoungGD, MiliciAJ, VossJ, et al. (2018). Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology, 90:e2146–e2154.
5.
Aartsma-RusA and Arechavala-GomezaV. (2018). Why dystrophin quantification is key in the eteplirsen saga. Nat Rev Neurol, 14:454–456.
6.
MendellJR, GoemansN, LowesLP, AlfanoLN, BerryK, ShaoJ, KayeEM and MercuriE. (2016). Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol, 79:257–271.
7.
KhanN, EliopoulosH, HanL, KinaneTB, LowesLP, MendellJR, Gordish-DressmanH, HenricsonEK and McDonaldCM. (2019). Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. J Neuromuscul Dis, 6:213–225.
8.
Aartsma-RusA, HegdeM, Ben-OmranT, BuccellaF, FerliniA, GallanoP, HowellRR, LeturcqF, MartinAS, et al. (2019). Evidence-based consensus and systematic review on reducing the time to diagnosis of Duchenne muscular dystrophy. J Pediatr, 204:305–313.e314.
9.
Aartsma-RusA, GinjaarIB and BushbyK. (2016). The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet, 53:145–151.
10.
RoshmiRR and YokotaT. (2019). Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc), 55:627–639.
11.
TsoumpraMK, FukumotoS, MatsumotoT, TakedaS, WoodMJA and AokiY. (2019). Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine, 45:630–645.
12.
LiQ, XuM, CuiY, HuangC and Sun.M (2017). Arginine-rich membrane-permeable peptides are seriously toxic. Pharmacol Res Perspect, 5. DOI: 10.1002/prp2.334
13.
AupyP, EchevarriaL, RelizaniK, ZarroukiF, HaeberliA, KomisarskiM, TensorerT, JouvionG, SvinartchoukF, GarciaL and GoyenvalleA. (2019). Identifying and avoiding tcDNA-ASO sequence-specific toxicity for the development of DMD exon 51 skipping therapy. Mol Ther Nucleic Acids, 19:371–383.
14.
Aartsma-RusA, StraubV, HemmingsR, HaasM, Schlosser-WeberG, Stoyanova-BeninskaV, MercuriE, MuntoniF, SepodesB, VroomE and BalabanovP. (2017). Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther, 27:251–259.
